GlassScriptPhysician profile
Navid Farahbakhsh
NPI 1780260208
$8,019.36
in general payments reported to CMS, 2019-2025
16 companies · $1,500 in 2025
The $1,500 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $684 · 2023: $2,291 · 2024: $3,544 · 2025: $1,500.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,786 · Consulting Fee: $1,103 · Travel and Lodging: $412 · Education: $33.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,786.32 |
| Consulting Fee | $1,102.50 |
| Travel and Lodging | $412.31 |
| Education | $33.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $2,545.47 | 2024-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $1,055.33 | 2022-2024 | Dupixent |
| Abbvie INC. | $1,034.46 | 2023-2025 | |
| Galderma Laboratories, L.P. | $676.29 | 2022-2025 | Nemluvio, Aklief, Twyneo |
| Novartis Pharmaceuticals Corporation | $559.84 | 2024-2025 | |
| Ucb, INC. | $368.30 | 2023-2025 | Cimzia, Bimzelx |
| Genzyme Corporation | $358.83 | 2023-2025 | |
| Lilly USA, LLC | $265.70 | 2024-2025 | Olumiant, Ebglyss |
| Boehringer Ingelheim Pharmaceuticals, INC. | $233.47 | 2023-2025 | Spevigo |
| Dermavant Sciences, INC. | $207.82 | 2023 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $130.71 | 2023 | Sotyktu |
| Almirall LLC | $126.04 | 2024 | Klisyri |
| Regeneron Pharmaceuticals, INC. | $125.77 | 2023 | Dupixent |
| Incyte Corporation | $120.88 | 2023 | Opzelura |
| Amgen INC. | $118.40 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Krystal Biotech INC | $92.05 | 2023 | Vyjuvek |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Navid Farahbakhsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.